Sanofi
Sanofi and Teva partner for development of inflammatory bowel disease treatment
October 4, 2023Medical Communications Crohn’s disease, Gastrointestinal tract, Sanofi, Teva, bowel disease, ulcerative colitis
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation of TEV’574, a treatment for …
Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review
September 26, 2023Medical Communications Dupixent, Ear Nose & throat, FDA, Regeneron, Sanofi
Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has accepted their supplemental Biologics License …
Pharmanovia acquires CNS portfolio from Sanofi
September 20, 2023Medical Communications CNS, Neurology, Pharmanovia, Sanofi, acquisition
Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a selection of central nervous system …
Innate Pharma doses first patient in relapsed/refractory multiple myeloma trial
July 11, 2023Research and Development Innate Pharma, Oncology, Sanofi, clinical trial, multiple myeloma
Innate Pharma has announced that the first patient has been dosed in its Sanofi-sponsored phase 1/2 clinical trial, which aims …
Sanofi shares data about new drug for haemophilia A in paediatric patients
June 26, 2023Research and Development Haematology, Sanofi, clinical trial, haemophilia a
Sanofi has shared new data from the phase 3 XTEND-Kids study which assessed Altuviiio (Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein) …
Innate Pharma announces drug researched with Sanofi receives FDA Fast Track Designation
June 8, 2023Research and Development Cancer, FDA, Haematology, Innate Pharma, Sanofi, haematology
Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US Food and Drug Administration (FDA) …
Sanofi announce positive phase 2 data for MS drug frexalimab
June 1, 2023Research and Development Neurology, Sanofi, clinical trial, frexalimab, multiple sclerosis
French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 clinical study into its relapsing …
Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment
May 3, 2023Sales and Marketing License Agreement, Pompe disease, Rare Diseases, Sanofi, maze therapeutics, treatment
Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement for Maze’s gluogen synthase 1 …
Sanofi complete acquisition of mRNA company Translate Bio
September 15, 2021Research and Development 2021, 3.2 billion, COVID-19, Sanofi, Translate Bio, acquisition, mrna, vaccines
French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal for Translate Bio, a Massachusetts-based …
Sanofi’s NSCLC drug gains EC approval
June 25, 2021Medical Communications EC, EU, NSCLC, Sanofi
The European Commission (EC) has approved Sanofi and Regeneron’s PD-1 inhibitor, Libtayo (cemiplimab), for the first-line treatment of adults with …
Sanofi’s Libtayo shows positive Phase III results in advanced cervical cancer
May 13, 2021Libtayo, Sanofi, cemiplimab, cervical cancer
Regeneron Pharmaceuticals and Sanofi have announced today positive Phase III trial results investigating the PD-1 inhibitor Libtayo (cemiplimab) in patients …
Sanofi to collaborate with Stanford University in immunology research
May 6, 2021Sanofi
Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine, working to advance the understanding of …
Sanofi’s RSV drug sees Phase III clinical trial success
April 26, 2021Sales and Marketing AstraZeneca, Sanofi
Sanofi have announced positive topline results from the Phase III MELODY trial into nirsevimab, which demonstrated protection against respiratory syncytial …
Sanofi signs €414 million deal for C4XD oral IL-17A inhibitor programme
April 19, 2021Sales and Marketing Sanofi
Sanofi has signed an exclusive worldwide licensing agreement with C4X Discovery Limited for C4XD’s oral pre-clinical IL-17A inhibitor programme, which …
Sanofi multiple myeloma drug approved for second indication by EC
April 19, 2021Sales and Marketing European Commission, Sanofi, Sarclisa, pharma, pharma news
The European Commission (EC) has approved a second indication of Sanofi’s Sarclisa drug for the treatment of adult patients with …
Latest content
Five Facts about cardiovascular disease
